Skip to main content
. 2016 Aug 2;24(8):1435–1443. doi: 10.1038/mt.2016.137

Figure 3.

Figure 3

Ad5-CMV-mTNFα/Ad5-CMV-mIL2 dual virus combination together with adoptive T-cell transfer. Adenoviruses coding for mTNFα and mIL2 were combined in a 1 to 1 ratio (0.5 × 109 VP of each virus) to treat B16-OVA tumors together with adoptive transfer of 1.5 × 106 CD8-enriched OT-I T-cells. Virus treatments continued every 7 days. Error bars, mean + SEM, n = 8. *P < 0.05, ***P < 0.001.